U.S. Markets closed
  • S&P 500

    3,465.39
    +11.90 (+0.34%)
     
  • Dow 30

    28,335.57
    -28.09 (-0.10%)
     
  • Nasdaq

    11,548.28
    +42.28 (+0.37%)
     
  • Russell 2000

    1,640.50
    +10.25 (+0.63%)
     
  • Crude Oil

    39.78
    -0.86 (-2.12%)
     
  • Gold

    1,903.40
    -1.20 (-0.06%)
     
  • Silver

    24.70
    -0.01 (-0.04%)
     
  • EUR/USD

    1.1868
    +0.0042 (+0.3560%)
     
  • 10-Yr Bond

    0.8410
    -0.0070 (-0.83%)
     
  • Vix

    27.55
    -0.56 (-1.99%)
     
  • GBP/USD

    1.3038
    -0.0042 (-0.3207%)
     
  • USD/JPY

    104.7200
    -0.1200 (-0.1145%)
     
  • BTC-USD

    13,122.99
    +226.40 (+1.76%)
     
  • CMC Crypto 200

    260.05
    -1.40 (-0.54%)
     
  • FTSE 100

    5,860.28
    +74.63 (+1.29%)
     
  • Nikkei 225

    23,516.59
    +42.32 (+0.18%)
     

NEXTCURE, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York against NextCure, Inc.

Wolf Haldenstein Adler Freeman & Herz LLP
·3 mins read

LEAD PLAINTIFF DEADLINE IS NOVEMBER 20, 2020

NEW YORK, Sept. 23, 2020 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a federal securities class action lawsuit has been filed against NextCure, Inc. (“NextCure” or the “Company”) (NASDAQ: NXTC) in the United States District Court for the Southern District of New York on behalf of those who purchased or acquired the securities of NextCure between November 5, 2019 and July 14, 2020, inclusive (the “Class Period”).

All investors who purchased shares of NextCure, Inc. and incurred losses are urged to contact the firm immediately at classmember@whafh.com or (800) 575-0735 or (212) 545-4774. You may obtain additional information concerning the action or join the case on our website, www.whafh.com.

If you have incurred losses in the shares of NextCure, Inc., you may, no later than November 20 , 2020, request that the Court appoint you lead plaintiff of the proposed class. Please contact Wolf Haldenstein to learn more about your rights as an investor in the shares of NextCure, Inc.

CLICK HERE TO JOIN CASE

The filed Complaint alleges that statements made by Defendants concerning the effectiveness of NC318, the responses observed in patients treated with NC318, and NC318’s potential to treat patients’ refractory to PD-1 therapies were false and misleading. NextCure had been developing NC318 using proceeds from a 2018 research and development collaboration agreement with Eli Lilly. On January 13, 2020, NextCure announced that Eli Lilly had ended its deal with the Company. Following this news, NextCure’s stock fell $4.70 per share, or approximately 8.3%, to close at $52.00 per share on January 13,
2020.

Then, pre-market on July 13, 2020, NextCure provided an interim update on the Phase 2 portion of its NC318 Monotherapy Phase 1/2 Trial, revealing that the Company was no longer planning to advance the non-small cell lung cancer and ovarian cancer cohorts in the Stage 2 portion of the Simon 2-stage trial, citing clinical response data and current enrollment criteria. The Company also announced the resignation of its Chief Medical Officer.

On this news, NextCure’s shares, which had closed at $17.88 per share on Friday, July 10, 2020, dropped over 54% on the next trading day, to close at $8.15 per share on July 13, 2020.

Wolf Haldenstein has extensive experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country. The firm has attorneys in various practice areas; and offices in New York, Chicago and San Diego. The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly recognized by the courts, which have appointed it to major positions in complex securities multi-district and consolidated litigation.

If you wish to discuss this action or have any questions regarding your rights and interests in this case, please immediately contact Wolf Haldenstein by telephone at (800) 575-0735, via e-mail at classmember@whafh.com, or visit our website at www.whafh.com.

Contact:

Wolf Haldenstein Adler Freeman & Herz LLP
Kevin Cooper, Esq.
Gregory Stone, Director of Case and Financial Analysis
Email: gstone@whafh.com, kcooper@whafh.com or classmember@whafh.com
Tel: (800) 575-0735 or (212) 545-4774

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.